BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30887761)

  • 21. Clear-cell and papillary serous cancer: treatment options.
    Tropé C; Kristensen GB; Abeler VM
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):433-46. PubMed ID: 11476564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
    Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
    BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uterine papillary serous carcinoma: patterns of failure and survival.
    Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
    McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
    Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.
    Huh WK; Powell M; Leath CA; Straughn JM; Cohn DE; Gold MA; Falkner CA; Carey DE; Herzog T; Fowler JM; Partridge EE; Kilgore LC; Alvarez RD
    Gynecol Oncol; 2003 Dec; 91(3):470-5. PubMed ID: 14675664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
    Qu XM; Velker VM; Leung E; Kwon JS; Elshaikh MA; Kong I; Logie NA; Mendez LC; van der Putten LJ; Donovan EK; Munkarah AR; Wiebe EM; Parra-Herran C; Warner A; Louie AV; D'Souza DP
    Gynecol Oncol; 2018 May; 149(2):283-290. PubMed ID: 29544706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy.
    Chang-Halpenny CN; Natarajan S; Hwang-Graziano JM
    Am J Clin Oncol; 2018 Apr; 41(4):371-378. PubMed ID: 26950465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study.
    Gadducci A; Cosio S; Landoni F; Maggino T; Zola P; Fuso L; Sartori E
    Int J Gynecol Cancer; 2012 Oct; 22(8):1355-60. PubMed ID: 22976496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
    Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
    Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
    Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
    Wilkinson-Ryan I; Frolova AI; Liu J; Stewart Massad L; Thaker PH; Powell MA; Mutch DG; Hagemann AR
    Int J Gynecol Cancer; 2015 Jan; 25(1):63-8. PubMed ID: 25365590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma.
    Stewart KD; Martinez AA; Weiner S; Podratz K; Stromberg JS; Schray M; Mitchell C; Sherman A; Chen P; Brabbins DA
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):527-35. PubMed ID: 12243832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
    Mundt AJ; McBride R; Rotmensch J; Waggoner SE; Yamada SD; Connell PP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1145-53. PubMed ID: 11483323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
    Xiang M; English DP; Kidd EA
    Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
    Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
    Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?
    Velker V; D'Souza D; Prefontaine M; McGee J; Leung E
    Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes in surgical stage I uterine papillary serous carcinoma.
    Havrilesky LJ; Secord AA; Bae-Jump V; Ayeni T; Calingaert B; Clarke-Pearson DL; Berchuck A; Gehrig PA
    Gynecol Oncol; 2007 Jun; 105(3):677-82. PubMed ID: 17355889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.